ANEW MEDICAL (OTC: LEAS) is poised to disrupt the biopharma industry in a way that hasn’t been seen in decades. Cell and gene therapies are the next wave of therapeutic innovation in the life sciences industry and the practice of medicine. ANEW is dedicated to realizing the potential of gene therapies to offer transformative patient outcomes in areas of high unmet medical need and extending the reach of gene therapies to highly prevalent neurodegenerative disorders like Alzheimer’s and Parkinson’s disease, and amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s disease”). ANEW has assembled a portfolio of gene therapies in partnership with leading scientific institutions, and they have built a core team with extensive experience in the gene therapy, drug development, and the commercialization process. As part of their ongoing business strategy, the company continues to explore potential opportunities to acquire or license new product candidates, as well as opportunities for partnership or collaboration on their existing products in development. The vision is to build one of the world’s leading cell and gene therapy company focused on the prevention and treatment of Alzheimer’s Disease (“AD”) and other neurodegenerative diseases by progressing their current α-Klotho-based AD and ALS programs. The company is an early-stage venture, with research and preclinical programs leading to first-in-man clinical trials of the “anti-aging” α-Klotho gene plasmids delivered inside cells by various means to include lipid nano-particles, electroporation, AAV, and Lentivirus. ANEW is also developing the recombinant secreted Klotho protein (s-KL) and mRNA for injections or infusions to slow cellular and/or systemic aging pathologies to include neurodegenerative diseases, cardiovascular diseases, chronic kidney diseases, fibrosis, bone and muscle wasting, and cancer. The inventors and technical expertise in the company’s academic labs in the U.S. and Spain will help us to achieve these goals and objectives. The company’s management team has done this before – created value in raw technology with great potential, and then conclude deals with corporate partners to buy the company or to license its key assets. Because of the very broad reach in therapeutic activities of the human α-Klotho protein – neurodegeneration, cancer, cardiovascular disease, fibrosis, bone and muscle, chronic kidney disease – e.g. age-related pathologies in general, there are a staggering number of potential clinical applications that can be developed and out-licensed, while other applications can be retained and commercialized by the company. The successful development of a single cell and/or gene therapy product for this broad array of applications is the objective. For more information, visit the company’s website at www.anewmeds.com.
To view IBN’s virtual coverage of Investor Summit Group’s Q4 Event, visit https://ibn.fm/InvestorSummit2022Q4Portal
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the companies participating at this quarter’s Investor Summit. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Los Angeles, California